Precision Medicine Market Size, Share, By Type (Diagnostics, Therapeutics, and Others), Technology (Bioinformatics, Drug Discovery, Gene Sequencing, Precision Molecular Diagnostics, Big Data Analytics, and Others), Application (Oncology, CNS, Respiratory, Immunology, Hematology, and Others), End-User (Pharmaceutical and Biotechnology Companies, Diagnostic Laboratories, Contract Research Organizations, and Others), and Region - Trends, Analysis, and Forecast till 2035

• Thermo Fisher Scientific Inc.
• AstraZeneca
• F. Hoffmann-La Roche Ltd
• Merck KGaA
• Illumina, Inc.
• Novartis Pharmaceuticals Corporation
• Bristol-Myers Squibb Company
• GE HealthCare
• Tempus
• Medtronic
• Precision Medicine Group, LLC
• Koninklijke Philips N.V.
• Pfizer Inc.
• Agilent Technologies, Inc.

Recent News:

• The National Institutes of Health (NIH) had launched a proof-of-concept precision medicine clinical trial to test new treatment combinations targeting specific genetic changes in the cancer cells of people with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), in October 2024. The trial, funded by NIH's National Cancer Institute (NCI), aimed to accelerate the discovery of more tailored treatments for these aggressive cancers of the blood and bone marrow.
• Ataraxis AI, the leading AI precision medicine company, emerged from stealth with USD 4 million in seed financing co-led by Giant Ventures and Obvious Ventures, in October 2024. The funding, had enabled Ataraxis to develop groundbreaking AI-powered diagnostic tests that significantly enhanced the prediction of patient outcomes and enabled more precise, personalized treatments.